Unknown

Dataset Information

0

Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac).

ABSTRACT:

SUBMITTER: Li X 

PROVIDER: S-EPMC9758065 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac).

Li Xue X   Peng Kuan K   Cheng Franco W T FWT   Lam David C L DCL   Cheung Ching Lung CL   Chui Celine S L CSL   Lai Francisco T T FTT   Wan Eric Y F EYF   Wong Carlos K H CKH   Ma Tiantian T   Yum Samson H H SHH   Chan Esther W Y EWY   Huang Jian Dong JD   Lau Chak Sing CS   Ip Mary S M MSM   Wong Ian C K ICK  

The Journal of infection 20221217 3

Similar Datasets

Unknown Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.
| S-EPMC8367195 | biostudies-literature
Unknown T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine.
| S-EPMC9501140 | biostudies-literature
Unknown Risk of glomerular diseases, proteinuria and hematuria following mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines.
| S-EPMC9620371 | biostudies-literature
Unknown Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination.
| S-EPMC9575314 | biostudies-literature
Unknown Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
| S-EPMC9212142 | biostudies-literature
Unknown Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.
| S-EPMC9155880 | biostudies-literature
Unknown Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
| S-EPMC8926447 | biostudies-literature
Unknown Booster dose of BNT162b2 in a CoronaVac primary vaccination protocol improves neutralization of SARS-CoV-2 Omicron variant.
| S-EPMC8963699 | biostudies-literature
Unknown Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
| S-EPMC8938264 | biostudies-literature
Unknown Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines.
| S-EPMC9376738 | biostudies-literature